News
LNTH
100.95
-0.12%
-0.12
Best Buy, Yarrow, Apple, Lantheus, Intuit Trending With Analysts
TipRanks · 1d ago
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Barchart · 2d ago
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)
TipRanks · 3d ago
*Lantheus Holdings 2Q EPS $1.11 >LNTH
Dow Jones · 3d ago
*Lantheus Holdings 2Q Net $75M >LNTH
Dow Jones · 3d ago
*Lantheus Holdings 2Q Rev $388.2M >LNTH
Dow Jones · 3d ago
*Lantheus Holdings 2Q Adj EPS $1.55 >LNTH
Dow Jones · 3d ago
Lantheus Holdings: Q2 Earnings Snapshot
Barchart · 3d ago
Lantheus Holdings Q2 2026 Earnings Preview
Seeking Alpha · 4d ago
Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
Benzinga · 5d ago
Lantheus downgraded to Market Perform from Outperform at CJS Securities
TipRanks · 5d ago
Curium to Acquire Lantheus, Taking Company Private
TipRanks · 5d ago
Lantheus Holdings Cut to Market Perform From Outperform by William Blair
Dow Jones · 6d ago
Lantheus Holdings Price Target Cut to $102.50/Share From $110.00 by TD Cowen
Dow Jones · 6d ago
Lantheus Holdings Cut to Hold From Buy by TD Cowen
Dow Jones · 6d ago
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Lantheus (LNTH)
TipRanks · 6d ago
TD Cowen Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
Benzinga · 6d ago
Lantheus downgraded to Hold from Buy at Truist
TipRanks · 6d ago
Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders
Benzinga · 6d ago
Midday Fly By: Amazon passes $3T market cap, Astra in tie-up talks with Bristol
TipRanks · 6d ago
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.